Alliance Global Partners analyst James Molloy lowered the firm’s price target on Can-Fite BioPharma (CANF) to $4.50 from $12 and keeps a Buy rating on the shares following the Q4 report. The company announced multiple clinical and developmental milestones outlined for its lead oral A3 adenosine receptor agonist candidates, Piclidenoson and Namodenoson, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF: